A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma.

A novel genome-wide screen that combines patient outcome analysis with array comparative genomic hybridization and mRNA expression profiling was developed to identify genes with copy number alterations, aberrant mRNA expression, and relevance to survival in glioblastoma. The method led to the discovery of physical gene clusters within the cancer genome with boundaries defined by physical proximity, correlated mRNA expression patterns, and survival relatedness. These boundaries delineate a novel genomic interval called the functional common region (FCR). Many FCRs contained genes of high biological relevance to cancer and were used to pinpoint functionally significant DNA alterations that were too small or infrequent to be reliably identified using standard algorithms. One such FCR contained the EphA2 receptor tyrosine kinase. Validation experiments showed that EphA2 mRNA overexpression correlated inversely with patient survival in a panel of 21 glioblastomas, and ligand-mediated EphA2 receptor activation increased glioblastoma proliferation and tumor growth via a mitogen-activated protein kinase-dependent pathway. This novel genome-wide approach greatly expanded the list of target genes in glioblastoma and represents a powerful new strategy to identify the upstream determinants of tumor phenotype in a range of human cancers.

[1]  S. Ashley,et al.  EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma , 2004, Oncogene.

[2]  M. Kanamori,et al.  EPHA2/EFNA1 expression in human gastric cancer , 2005, Cancer science.

[3]  R. Hamoudi,et al.  Molecular and cytogenetic analysis of glioblastoma multiforme. , 2000, Cancer genetics and cytogenetics.

[4]  J. Nesland,et al.  PROGNOSTIC VALUE OF EPHA2 AND EPHRINA-1 IN SQUAMOUS CELL CERVICAL CARCINOMA , 2004, International Journal of Gynecologic Cancer.

[5]  I. Pollack,et al.  EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. , 2005, Neoplasia.

[6]  M. Kinch,et al.  Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1 , 2004, Cancer Gene Therapy.

[7]  W. Debinski,et al.  EphA2 as a Novel Molecular Marker and Target in Glioblastoma Multiforme , 2005, Molecular Cancer Research.

[8]  S. Ashley,et al.  Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. , 2004, Biochemical and biophysical research communications.

[9]  Nicolas Stransky,et al.  Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas. , 2005, Cancer research.

[10]  Ivan Smirnov,et al.  Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma , 2005, Clinical Cancer Research.

[11]  Ho-Keung Ng,et al.  Detection of Multiple Gene Amplifications in Glioblastoma Multiforme Using Array-Based Comparative Genomic Hybridization , 2001, Laboratory Investigation.

[12]  L. Chin,et al.  High-resolution characterization of the pancreatic adenocarcinoma genome , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  K. Aldape,et al.  Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. , 2005, Cancer research.

[14]  I. Kohane,et al.  Inter-species differences of co-expression of neighboring genes in eukaryotic genomes , 2004, BMC Genomics.

[15]  M. Ringnér,et al.  Impact of DNA amplification on gene expression patterns in breast cancer. , 2002, Cancer research.

[16]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Langermann,et al.  Differential EphA2 epitope display on normal versus malignant cells. , 2003, Cancer research.

[18]  Peter J. Park,et al.  Comparative analysis of algorithms for identifying amplifications and deletions in array CGH data , 2005, Bioinform..

[19]  L. Recht,et al.  High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. , 2005, Cancer research.

[20]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[21]  Siew Hong Leong,et al.  A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. , 2003, Cancer research.

[22]  Eytan Domany,et al.  Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. , 2003, Cancer research.

[23]  Sampsa Hautaniemi,et al.  High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. , 2004, Neoplasia.

[24]  I. Derweesh,et al.  Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  T. Pawson,et al.  EphB receptor activity suppresses colorectal cancer progression , 2005, Nature.

[26]  中原 由紀子 Detrended fluctuation analysis of genome-wide copy number profiles of glioblastomas using array-based comparative genomic hybridization , 2005 .

[27]  A. Pozzi,et al.  Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo , 2002, Oncogene.

[28]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[29]  Ajay N. Jain,et al.  Hidden Markov models approach to the analysis of array CGH data , 2004 .

[30]  D. Brat,et al.  Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. , 2004, Neuro-oncology.

[31]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Kinch,et al.  EphA2 overexpression causes tumorigenesis of mammary epithelial cells. , 2001, Cancer research.

[33]  A. Sood,et al.  EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma , 2004, Clinical Cancer Research.

[34]  Naoki Kagawa,et al.  Genetic analysis of human glioblastomas using a genomic microarray system , 2006, Brain Tumor Pathology.

[35]  Yidong Chen,et al.  High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. , 2004, Neoplasia.

[36]  R. Kandpal,et al.  Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. , 2004, Biochemical and biophysical research communications.

[37]  R. Tibshirani,et al.  A method for calling gains and losses in array CGH data. , 2005, Biostatistics.

[38]  M. Kinch,et al.  Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. , 2002, Cancer research.

[39]  R. Klein,et al.  Eph receptors and ephrins: effectors of morphogenesis. , 1999, Development.

[40]  Thomas Koschny,et al.  Comparative genomic hybridization in glioma: a meta-analysis of 509 cases. , 2002, Cancer genetics and cytogenetics.

[41]  M. Kinch,et al.  Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade , 2002, Oncogene.

[42]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  F. Kokocinski,et al.  Microarray‐based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression , 2005, International journal of cancer.

[44]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.